Our findings on parkin ubiquitylating PKM2 at Lys-186 and Lys-206 and inhibiting PKM2 enzymatic activity revealed another post-translational modification event to regulate PKM2 functions and provided a new way to modulate PKM2 activity for certain cancer and Parkinson disease therapy. The gene discussed is PRKN; the disease is cancer.